Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:17:36 EDT Mon 24 Mar 2025
Enter Symbol
or Name
USA
CA



Q:FDMT - 4D MOLECULAR THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FDMT - Q0.13.25·4.770.13.92+0.174.51,297.34,6825,7063.68  3.94  3.5836.25  3.66Mar 21Mar 1015 min RT 2¢

Recent Trades - Last 10 of 5706
Time ETExPriceChangeVolume
19:19:45Q4.100.3551
17:48:38Q3.950.2017
16:41:43Q3.950.2069
16:40:10Q3.940.19253
16:22:56Q3.920.1762
16:13:48Q3.920.172,638
16:13:40Q3.920.1767,536
16:10:02Q3.800.052
16:07:04Q3.920.1764,898
16:05:12Q3.920.171

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-03-10 08:00U:FDMTNews Release4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
2025-02-28 16:05U:FDMTNews Release4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
2025-02-19 08:01U:FDMTNews Release4DMT to Participate in Upcoming Investor Conferences
2025-02-08 14:30U:FDMTNews Release4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
2025-01-29 08:00U:FDMTNews Release4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
2025-01-10 08:00U:FDMTNews Release4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
2025-01-10 08:00U:FDMTNews Release4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
2024-12-16 08:00U:FDMTNews Release4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
2024-11-14 08:00U:FDMTNews Release4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
2024-11-13 16:05U:FDMTNews Release4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
2024-09-23 08:00U:FDMTNews Release4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
2024-09-18 16:05U:FDMTNews Release4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
2024-09-05 08:00U:FDMTNews Release4DMT Announces Presentations at Upcoming Retina Conferences
2024-09-03 08:00U:FDMTNews Release4DMT to Participate in the 2024 Cantor Global Healthcare Conference
2024-08-27 08:00U:FDMTNews Release4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
2024-08-12 08:00U:FDMTNews Release4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
2024-08-08 16:05U:FDMTNews Release4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
2024-08-05 08:00U:FDMTNews Release4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
2024-07-17 05:00U:FDMTNews Release4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
2024-06-24 08:00U:FDMTNews Release4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy